H3N2 Influenza Pseudovirus

Comprehensive Neutralization Assay Solutions for Advancing Influenza Research

Get your pseudovirus

H3N2 pseudovirus Advantages

We produce a pseudovirus pseudotyped exclusively with the hemagglutinin protein of the influenza strain A/Hong Kong/1/1968 (H3N2) (GenBank: AAK51719.1), which was responsible for the outbreak in Hong Kong in 1968. These pseudoviruses carry a modified genome that expresses a luciferase or a GFP reporter gene.

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293T cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of hemagglutinin as the sole surface antigen

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 10 month at -80 °C

Support high-throughput screening

QC report Order Now

H3N2 Pseudovirus Applications

Pseudoviruses provide a safe and versatile platform for influenza virus research and the development of therapeutic countermeasures. Influenza pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the influenza virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

Order Now

H3N2 Influenza Virus Background

H3N2 is a subtype of influenza A virus that emerged during the 1968 Hong Kong pandemic, causing widespread illness and significant global mortality. The A/Hong Kong/1/1968 (H3N2) strain carries 8 segmented RNA genomes (ranging from 890 to 2,341 nucleotides), each coding for key viral proteins involved in replication, transcription, and host infection. Its surface glycoprotein hemagglutinin (HA) is essential for binding to sialic acid receptors on human respiratory epithelial cells, initiating viral entry via endocytosis. Following membrane fusion, the viral genome is delivered into the host nucleus for replication. As a virus that continues to evolve through antigenic drift, H3N2 remains a central target in seasonal influenza surveillance and vaccine formulation efforts worldwide.

H3N2 Pseudovirus in Publications

The continued circulation of influenza A (H3N2) viruses, including the historically significant A/Hong Kong/1/1968 strain, highlights the ongoing need for effective vaccines and antiviral strategies. The pseudovirus neutralization assay, which can be performed safely in standard laboratory settings, provides a rapid and efficient platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the hemagglutinin (HA) of H3N2 viruses.

• Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains
• Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018–2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin

Documentations

Quality Control Reports

Access all reports

SDS

Access SDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL